ObjectiveTo explain the rationale and protocol of the methods and analyses to be used
in the LIVER-PAM randomized clinical trial, which seeks to understand
whether a higher mean arterial pressure is capable of reducing the incidence
of renal dysfunction postoperatively after liver transplantation.MethodsLIVER-PAM is an open-label, randomized, controlled, singlecenter clinical
trial. Patients randomized to the intervention group will have a mean
arterial pressure of 85 - 90mmHg in the initial 24 hours of postoperative
management, while patients in the control group will have a mean arterial
pressure of 65 - 70mmHg in the same period. A sample of 174 patients will be
required to demonstrate a 20% reduction in the absolute incidence of renal
dysfunction, with a power of 80% and an alpha of 0.05.ConclusionIf a 20% reduction in the absolute incidence of renal dysfunction in the
postoperative period of liver transplantation is achieved with higher target
mean arterial pressure in the first 24 hours, this would represent an
inexpensive and simple therapy for improving current outcomes in the
management of liver transplant patients.ClinicalTrials.gov Registry:NCT05068713